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volume targets in the IBCL seed group and the loose seed 
group. Brachytherapy was performed using a dynamic dose 
calculation technique. Computed tomography/magnetic 
resonance imaging fusion-based dosimetry was performed 1 
month after brachytherapy. Post-implant dose volume 
histogram (DVH) parameters, prostate sector dosimetry, 
operation time, seed migration, and toxicities were 
compared between the two groups. A sector analysis tool was 
used to divide the prostate into six sectors (anterior and 
posterior sectors at the base, mid-gland, and apex). Analyses 
were performed using the 2-sample t test for continuous data 
that followed a normal distribution, the Mann-Whitney test 
for continuous data that did not follow a normal distribution, 
and the Chi-squared test for categorical data. Probability (P) 
values of < 0.05 were considered significant. 
 
Results: In prostate sector dosimetry, V100 (95.3% vs. 89.7%; 
P = 0.014) and D90 (169.7 Gy vs. 152.6 Gy; P = 0.013) in the 
anterior base sector were significantly higher in the IBCL 
seed group than in the loose seed group. Other post-implant 
DVH parameters did not differ significantly between the two 
groups. The seed migration rate was significantly lower in the 
IBCL seed group than in the loose seed group (6% vs. 66%; P < 
0.001). There was no significant difference in mean operation 
time between the two groups; however, mean operation time 
per seed was significantly longer in the IBCL seed group than 
in the loose seed group (1.31 min vs. 1.13 min; P = 0.003). 
The median follow-up was 18 months (range, 1-36 months). 
No significant differences in toxicities were seen between the 
two groups. 
 
Conclusion: Our study showed more dose coverage post-
operatively in the anterior base prostate sector and less seed 
migration in IBCL seeds implantation compared to loose seeds 
implantation. 
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Purpose or Objective: to evaluate results of saturation 
biopsy in candidates for focal, hemigland high dose rate 
(HDR) brachytherapy or irradiation with “low-dose tunnel for 
urethra” 
 
Material and Methods: Template guided saturation biopsy 
was performed in 52 primary patients with suspicion to 
prostate cancer and PSA below 10 ng/ml. Biopsy was 
performed under US control with the help of brachytherapy 
grid and 5mm distance between samples. During positioning 
and biopsy procedure we put special attention for accurate 
sampling of prostate in periurethral region. The number of 
cores varied from 17 to 50 (average 33 cores). Finally in 31 
patients with confirmed prostate cancer results of biopsy 
were used for brachytherapy planning. 
 
Results: Saturation biopsy revealed prostate cancer in 31 of 
52 evaluated patients. Involved volume ranged from 5% to 
100% (average - 57%). Focal nature of PC diagnosed in 6 
(19.4%), multifocal – in another 25 (80.6%) patients. 
Hemigland invasion mentioned in 10 cases. Saturation biopsy 
detected PC in periurethral cores in 22 (70.9%) of 31 
evaluated patients: invasion of one core revealed in 1, 2 
cores – in 6, 3 and more cores – in another 14 cases. In 10 
patients extent of involvement in periurethral cores varied 
between 10% and 50%, in another 12 observations exceeded 
50%. According to results obtained on saturation biopsy we 
performed HDR brachytherapy with “urethra low dose 
tunnel” (D10ur≤80%) in 9 patients with noninvolved 
periurethral cores. Theoretically hemigland brachytherapy 
was possible in 10 of 31 evaluated patients. 
 
Conclusion: in low risk patients with prostate cancer results 
of template guided saturation biopsy can significantly 
influence strategy of HDR brachytherapy 
 
EP-2001  
Radical salvage brachytherapy (BT) for local recurrences 
after previou radiation treatment 
S. Rodríguez Villalba
1Clinica Benidorm, Radiotherapy Department, Benidorm, 
Spain 
1, M. Santos Ortega1, M. Depiaggio1, L. De 
la Torre2, J. Martinez2, J. Canovas2, J. Richart1, A. Otal1, J. 
Perez Calatayud1 
2Hospital Marina Baixa, Urology Department, Villajoyosa- 
Alicante, Spain 
 
Purpose or Objective: We presented a retrospective analysis 
in 11 patients with histological proven local-recurrent 
prostate cancer, undergoing salvage BT, treated between 
February 2009 and December 2014. 
 
Material and Methods: The previous radical treatments 
were: 3 Low dose rate BT (LDR-BT) (145 Gy), one combined 
treatment with external radiotherapy (EBRT) (45 Gy) and 
LDR-BT (100 Gy), and 7 EBRT (68-74 Gy). Four patients have 
been rescued with LDR-BT and seven with High-Dose-Rate-BT 
(HDR-BT). All patients have a complete study with abdominal 
CT scan, pelvic MRI, and bone scan to diagnose local disease 
exclusively. LDR-BT patients received 145 Gy with 125I. HDR 
patients, has been treated with 30 Gy in 3 fractions of 10 Gy 
separated ten days. Median time to Biochemical failure (BF) 
from the first treatment was 48 months (12-114). All patients 
received previous hormonotherapy. Median time to rescue 
was 69 months (33-156). Toxicities were evaluated according 
with CTCAE scale (version 4.0). 
 
Results: Median follow-up: 26,5 months (3-72 m). The overall 
survival time was 98 months (65-174). At the end of the 
follow up, March of 2015, all patients are alive, nine (82%) 
without evidence of disease, one patients had a 
retroperitoneal failure 7 months after the salvage-BT and 
other patient was diagnosed of a solitary bone metastases at 
12 months. Median PSA nadir post-salvage-BT was 0.1 ng/ml 
(0-0,29). There were not grade 3 GU or GI toxicities. 100 % of 
LDR-BT patients presented acute GU-toxicity grade 2. Fifty-
seven % of the HDR-BT patients had GU-toxicity grade 1 (0% 
grade 2). 
 
Conclusion: Prostate BT is an effective and well tolerated 
reirradiation treatment in local-recurrent prostate cancer 
patients, with, few long-term toxicities, mainly in those 
treated with HDR-BT. 
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Purpose or Objective: The different conventional treatments 
for prostate cancer are multiple and for low-risk tumors, 
focal brachytherapy can be a therapeutic alternative option 
to active surveillance. However, this focal treatment remains 
still under evaluation and within the frame of the focal 
brachytherapy project conducted in Toulouse, we will 
present in this study two parts of the project: first, the 
contribution of multi-modal rigid and non-rigid registrations 
for localization and delineation of the treated volume, then 
the dosimetry evaluation after registration. 
 
Material and Methods: First step of prostate brachytherapy 
at our Institute consists in a contour-based non-rigid 
registration between MRI and US perfomed with Koelis 
software where positive biopsy trajectory is retrieved and a 
fiducial non-radioactive marker is implanted to localize the 
tumor focus. As a result of this localization, dosimetry was 
performed using VariSeed software, dose prescription is 
ESTRO 35 2016                                                                                                                                                    S947 
________________________________________________________________________________ 
160Gy to the PTV (GTV + 2mm) and Bard Quicklink system is 
used to implant I125 radioactive seeds. Multi-modal manual 
rigid and non-rigid transformations between MR and CT scans 
were performed on the first 9 patients with three software 
solutions: the treatment planning system Variseed, a 
research platform 3D Slicer and a commercial solution 
Mirada. MR onto CT registrations were approved by an expert 
uro-radiologist and quantitative evaluations of the 
registrations were performed by calculating the means of 
vectors displacement marked on four relevant points of 
interest detected on the I125 seeds. For the dosimetry, an 
assessment of the impact of these readjustments on the 
initial dose matrix was also performed in Mirada by applying 
the deformation to the initial contours and injecting the 
initial dose matrix. 
 
Results: For the first 9 patients, evaluation of registration 
gives means of vectors displacement of 1.52mm [0.36-2.6] 
with Variseed, 0.62mm [0.26-1.29] with 3D Slicer and 
0.42mm [0.24-0.81] with Mirada. Examples of fusions are 
illustrated in Figure1. Concerning the dosimetric data and 
considering the most relevant criteria from the initial 
outline, the D90%(Gy) to the prostate and respectively for 
the target has a mean difference of +0.68Gy and -12Gy. The 
D30%(Gy) and the D10%(Gy) to the urethra respectively have 
a mean difference of -0.99 and -5.58Gy. Lastly, D1cc(Gy) to 
the rectum has a mean difference of +4,37Gy. 
 
 
 
Conclusion: Target volume definition remains a crucial step 
for focal brachytherapy as only confirmed tumor biopsy sub-
volumes of the prostate are treated. Registration procedures 
tested in our institute confirmed the need to implement 
precise rigid and non-rigid fusion of image to delineate 
relevant target volumes on different modalities. In addition, 
dosimetry evaluation on the registrations showed the impact 
of the deformations in high dose gradients. 
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Purpose or Objective: The High-dose-rate brachytherapy as 
monotherapy in one fraction, is a treatment option in 
patients with low-risk prostate cancer and can be used as an 
alternative to the low-dose-rate brachytherapy.Compared to 
the low-dose-rate, the HDR as monotherapy has not proven 
long-term results with regard to disease control. It is not 
known what dose of treatment should be used to increase the 
biochemical control, survival control disease and reduce 
unaffordable toxic effects. 
 
Material and Methods: Results on patients treated with high-
dose-rate brachytherapy as monotherapy are presented 
below. 
Sample: A series of 75 patients between 2008 and 2013 
treated with high-dose-rate brachytherapy (HDR) single dose 
of 19 Gy (62) and 20.5 Gy (13) were selected. 
A technique of guided-ultrasound brachytherapy and 
dynamic-calculated intraoperative dose was used. 
 
Results: The results show an overall survival of 91.3% of 
patients, with survival free of disease of 97% and a 
biochemical control of 72.5%. 
Patients toxicity: Acute urinary toxicity: 53.8% (grade 2). 
Chronic urinary toxicity: 49.2% (grade 2). Acute 
gastrointestinal toxicity: 86.2% (grade 1). Chronic 
gastrointestinal toxicity: 89% (grade 1).Acute urinary 
retention rate of 2.9%. 
 
Conclusion: HDR prostate brachytherapy as monotherapy in 
one single fraction of 19 Gy does not provided adequate 
biochemical control and survival free disease rates. It is 
necessary more studies to establish what would be the most 
appropiate dose to obtain higher rates of disease control 
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Purpose or Objective: Evaluate the relationship between 
RTOG G2-G3 urinary morbidity after prostate brachytherapy 
and urethral doses at the end of real-time dosimetry 
planning. 
 
Material and Methods: From November 2007 to December 
2010, 204 prostate cancer patients underwent monotherapy 
I-125 seeds brachytherapy in our institution. Real-time US 
guided dosimetry planning was performed with Variseed 7.0 
or 8.0. Of the 204 patients, 11 (5.4%) developed an acute 
urinary retention and required a urinary catheter from 2 
weeks to 7 months (G2 morbidity), and 7 patients (3.4%) 
required a transurethral resection of the prostate (G3 
morbidity).  
In a retrospective study, detailed urethral dosimetry was 
evaluated at the end of the real-time implant. Assessed 
values included maximum dose, V80, V100, V150 and D90 for 
both overall urethra and segmented urethra (as base, 
midgland and apex urethra). 1.5-mm and 2.5-mm urethral 
expansions were also reviewed for all dosimetry parameters. 
To check if dose homogeneity around urethral regions was 
related to morbidity, subtraction of expanded minus non-
expanded urethral dosimetry parameters was also performed. 
In total, 111 parameters were reviewed.  
T-Student test and U Mann-Whitney test were used to 
compare differences between patients free of urinary 
morbidity from those presenting G2 and G3 morbidity. p 
<0.05 was considered significant. 
 
Results: No correlation was found between non-expanded 
urethra doses and urinary morbidity. 
Best result (p=0.005) for distinguishing free-morbidity cohort 
from G2-G3 morbidity-cohort was obtained for subtraction of 
the maximum dose of the non-expanded minus 2.5-mm-
expanded overall urethra.  
